Transcutaneous auricular vagal nerve stimulation improves functional dyspepsia by enhancing vagal efferent activity

Y Zhu, F Xu, D Lu, P Rong, J Cheng… - American Journal …, 2021 - journals.physiology.org
Y Zhu, F Xu, D Lu, P Rong, J Cheng, M Li, Y Gong, C Sun, W Wei, L Lin, JDZ Chen
American Journal of Physiology-Gastrointestinal and Liver …, 2021journals.physiology.org
This study was designed to investigate whether transcutaneous auricular vagal nerve
stimulation (taVNS) would be able to improve major pathophysiologies of functional
dyspepsia (FD) in patients with FD. Thirty-six patients with FD (21 F) were studied in two
sessions (taVNS and sham-ES). Physiological measurements, including gastric slow waves,
gastric accommodation, and autonomic functions, were assessed by the electrogastrogram
(EGG), a nutrient drink test and the spectral analysis of heart rate variability derived from the …
This study was designed to investigate whether transcutaneous auricular vagal nerve stimulation (taVNS) would be able to improve major pathophysiologies of functional dyspepsia (FD) in patients with FD. Thirty-six patients with FD (21 F) were studied in two sessions (taVNS and sham-ES). Physiological measurements, including gastric slow waves, gastric accommodation, and autonomic functions, were assessed by the electrogastrogram (EGG), a nutrient drink test and the spectral analysis of heart rate variability derived from the electrocardiogram (ECG), respectively. Thirty-six patients with FD (25 F) were randomized to receive 2-wk taVNS or sham-ES. The dyspeptic symptom scales, anxiety and depression scores, and the same physiological measurements were assessed at the beginning and the end of the 2-wk treatment. In comparison with sham-ES, acute taVNS improved gastric accommodation (P = 0.008), increased the percentage of normal gastric slow waves (%NSW, fasting: P = 0.010; fed: P = 0.007) and vagal activity (fasting: P = 0.056; fed: P = 0.026). In comparison with baseline, 2-wk taVNS but not sham-ES reduced symptoms of dyspepsia (P = 0.010), decreased the scores of anxiety (P = 0.002) and depression (P < 0.001), and improved gastric accommodation (P < 0.001) and the %NSW (fasting: P < 0.05; fed: P < 0.05) by enhancing vagal efferent activity (fasting: P = 0.015; fed: P = 0.048). Compared with the HC, the patients showed increased anxiety (P < 0.001) and depression (P < 0.001), and decreased gastric accommodation (P < 0.001) and %NSW (P < 0.001) as well as decreased vagal activity (fasting: P = 0.047). The noninvasive taVNS has a therapeutic potential for treating nonsevere FD by improving gastric accommodation and gastric pace-making activity via enhancing vagal activity.
NEW & NOTEWORTHY Treatment of functional dyspepsia is difficult due to various pathophysiological factors. The proposed method of transcutaneous auricular vagal nerve stimulation improves symptoms of both dyspepsia and depression/anxiety, and gastric functions (accommodation and slow waves), possibly mediated via the enhancement of vagal efferent activity. This noninvasive and easy-to-implement neuromodulation method will be well received by patients and healthcare providers.
American Physiological Society